
Commentary|Videos|July 25, 2025
How the Mechanisms of KRAS(ON) Inhibitors Differ From KRAS(OFF) Inhibitors
Fact checked by: Chris Ryan
Mike J. Pishvaian, MD, PhD, and Martin Dietrich, MD, PhD, discuss how KRAS(ON) inhibitors differ in mechanism from KRAS(OFF) inhibitors.
Advertisement
Advertisement
Related to this article

Check out this October recap of OncLive’s coverage of the top news and expert insights in gastrointestinal cancers.

The top 5 OncLive TV videos of the week cover insights in NSCLC, gynecologic cancers, CRC, multiple myeloma, and NMIBC.
Advertisement
Advertisement
Trending on OncLive
1
Patient Preferences Steer Decisions as Options Multiply Across EGFR-Mutated NSCLC
2
Tovorafenib Sustains Treatment-Free Intervals in R/R BRAF-Altered Pediatric Low-Grade Glioma
3
Dr Johnson on Immune Activation With Indoximod-Based Chemo-Immunotherapy in Recurrent Ependymoma
4
Dr Miller on Whole Genome Sequencing of CSF ctDNA in High-Grade Glioma
5


